Belatacept (Nulojix®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000600
English
Authors' recommendations:
Belatacept (Nulojix®) is not recommended as an option for use within NHS Wales, in combination with corticosteroids and a mycophenolic acid, for prophylaxis of graft rejection in adults receiving a renal transplant.
The case for cost effectiveness has not been proven.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=194845&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Immunosuppressive Agents
- Kidney Transplantation
- Graft Rejection
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.